EyePoint Pharmaceuticals, Inc.

Informe acción NasdaqGM:EYPT

Capitalización de mercado: US$628.3m

EyePoint Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Se prevé que los beneficios de EyePoint Pharmaceuticals disminuyan en un 1% al año, mientras que se espera que sus ingresos anuales crezcan en un 44.8% al año. Se prevé que el BPA crezca en un 5% por año. Se espera que la rentabilidad financiera sea de -81.8% en 3 años.

Información clave

-1.0%

Tasa de crecimiento de los beneficios

5.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals23.8%
Tasa de crecimiento de los ingresos44.8%
Rentabilidad financiera futura-81.8%
Cobertura de analistas

Good

Última actualización14 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 09
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Recent updates

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

Nov 14

Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%

Oct 29
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price

Sep 13
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price

EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

Aug 29

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Aug 15
These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 09
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

Jun 19
Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)

May 06

More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

Mar 31
More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time

Feb 20

Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

Feb 05
Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Jan 29
Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

Dec 18
Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Dec 13
These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

May 14
Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

Apr 17
Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space

Aug 30

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Jul 16
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD

Jul 15

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Mar 06
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:EYPT - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/20268-217-152-1908
12/31/202515-178-137-15811
12/31/202442-120-130-10611
9/30/202446-104-118-113N/A
6/30/202450-87-94-90N/A
3/31/202450-79-17-12N/A
12/31/202346-71-22N/A
9/30/202343-100912N/A
6/30/202337-1061214N/A
3/31/202340-102-64-62N/A
12/31/202241-102-67-65N/A
9/30/202242-78-71-69N/A
6/30/202241-77-64-64N/A
3/31/202239-67-55-55N/A
12/31/202137-58-50-50N/A
9/30/202133-54-28-28N/A
6/30/202139-42-19-19N/A
3/31/202134-44-14-13N/A
12/31/202034-45-15-14N/A
9/30/202036-40-32-32N/A
6/30/202023-52-48-48N/A
3/31/202026-51-60-60N/A
12/31/201920-57-57-57N/A
9/30/201914-58-56-56N/A
6/30/201912-75-53-53N/A
3/31/20196-98-42-42N/A
12/31/20185-86-34-33N/A
9/30/20183-80-28-28N/A
6/30/20183-53N/A-22N/A
3/31/20183-25N/A-20N/A
12/31/20173-23N/A-20N/A
9/30/20178-17N/A-20N/A
6/30/20178-18N/A-20N/A
3/31/20177-19N/A-20N/A
12/31/20167-19N/A-20N/A
9/30/20161-24N/A-18N/A
6/30/20162-22N/A-16N/A
3/31/20162-20N/A-15N/A
12/31/20152-20N/A-15N/A
9/30/20152-19N/A10N/A
6/30/2015276N/A10N/A
3/31/2015268N/A11N/A
12/31/20142810N/A13N/A
9/30/20142811N/A-11N/A
6/30/20143-13N/A-11N/A
3/31/20144-13N/A-11N/A
12/31/20132-14N/A-11N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que EYPT siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que EYPT siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que EYPT siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (44.8% al año) de EYPT crezcan más rápidamente que los del mercado US (9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (44.8% al año) de EYPT crezcan más rápidamente que un 20% al año.


Previsiones de crecimiento de los beneficios por acción


Rentabilidad financiera futura

ROE futura: EYPT se prevé que no sea rentable en 3 años.


Descubre empresas en crecimiento